RBC Capital increased its price target for CG Oncology shares, citing potential data from the PIVOT-006 trial in early June.
RBC Capital raised its price target for CG Oncology (NASDAQ:CGON) to $79 from $73, maintaining an Outperform rating. The firm highlighted PIVOT-006 as a key catalyst, expecting trial data in early June to show a 40% risk reduction and drive 20% upside in shares.
CG Oncology shares have surged 62% year-to-date, accelerated by the PIVOT-006 timeline. BofA also recently lifted its price target to $84 from $72, reaffirming a Buy rating and noting further upside potential.
The company focuses on bladder-sparing therapies, with cretostimogene in development for Non-Muscle Invasive Bladder Cancer (NMIBC).